Immune cell therapy for severe AL amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with AL amyloidosis (a rare condition where abnormal proteins build up in your organs).
- Your heart must be significantly affected (confirmed by blood tests and a heart ultrasound).
- You must have measurable signs of the disease in your blood or bone marrow.
- You must be well enough to perform daily activities (your doctor will check this).
- You must not have serious infections, recent treatments, or uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.